The session will dive into the current trends in Life Sciences Deal-Making and upcoming challenges due to the current geopolitical headwinds. We will be joined by experts from investment banking, biotech and big pharma to explore the challenges and opportunities that the industry currently faces. The discussion will delve into:
- The impact of the new U.S. administration on the industry
- How interest rate policies are shaping financial strategies
- Key insights on IPO trends and M&A activities
- Licensing opportunities and global influences, including China's biotech advancements
May 5, 17:30-18:15, room MCH Lounge
| Name | Position | Institution |
|---|---|---|
| Julia Schieber | Partner (Zurich) | Baker McKenzie |
| Name | Position | Institution |
|---|---|---|
| Oren Livne | Partner (New York) | Baker McKenzie |
| Lev Kogon | Vice President, Head of Business Development | Stealth Mode Biotech |
| Konrad Gehrke | Director Healthcare Investment Banking | Bank of America |
Baker McKenzie is one of the largest law firms in Switzerland, with offices in Geneva and Zurich. For more than half a century, and with a team of more than 120 lawyers, we have been a prominent force in the Swiss legal landscape, providing top-tier legal advice to domestic and foreign clients.
With decades of experience advising healthcare and life sciences companies on their global expansion, we understand the challenges industry players face and what it takes to overcome them. As trusted advisors to the world's largest pharmaceutical, biotech, medical device, medtech, digital health and healthcare services companies, our team of more than 800 lawyers includes professionals with scientific backgrounds and degrees offer comprehensive legal services, including transactional, regulatory, tax, intellectual property and other matters across the globe.
Our dedication to legal excellence is globally acknowledged, supported by our innovative solutions and an extensive global presence encompassing 74 offices across 45 countries.
